3.2. Factors associated with Outcome
Three-year OS and EFS of all patients were 70.7% and 62.1% respectively. Patients who were transplanted in CR1 had significantly better three-year OS (84.8%), than patients transplanted in CR2 (66.1%) and PR (26.7%), p=0.000 (Figure 1). Similarly, three-year EFS of patients who were transplanted in CR1 (78.8%) was significantly better than patients transplanted in CR2 (52.5%) and PR (26.7%), p=0.000. Patients who had marrow involvement had a significantly poorer three-year OS (50%) than patients who had no bone marrow involvement (75.9%), p=0.008. Similarly, three-year EFS of patients (68.8%) who had no marrow involvement was significantly better than patients with bone marrow involvement (35.7%), p=0.000. There was no significant difference in OS and EFS in patients with high risk IPI and low risk IPI group. Age, gender, and types of NHL were also not found to have significantly affected OS and EFS. With multiple variate analysis, patients who were transplant in CR1 had better compared to patients who were transplant in CR2 regardless of outcome, as shown in Table 2.